✦ LIBER ✦

Erratum to: Effect of Tramiprosate in Patients with Mild-to-moderate Alzheimer’s disease: Exploratory Analyses of the MRI sub-group of the Alphase study

✍ Scribed by S. Gauthier; P. S. Aisen; S. H. Ferris; D. Saumier; Anh Duong; D. Haine; D. Garceau; J. Suhy; J. Oh; W. Lau; J. Sampalis; for the Alphase Group

Book ID: 107670948
Publisher: Springer
Year: 2010
Tongue: English
Weight: 106 KB
Volume: 14
Category: Article
ISSN: 1279-7707
DOI: 10.1007/s12603-010-0015-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of tramiprosate in patients with

Effect of tramiprosate in patients with mild-to-moderate alzheimer’s disease: Exploratory analyses of the MRI sub-group of the alphase study

✍ S. Gauthier; P. S. Aisen; S. H. Ferris; D. Saumier; A. Duong; D. Haine; D. Garce 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

Domain-specific cognitive effects of tra

Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer’s disease: ADAS-cog subscale results from the Alphase study

✍ D. Saumier; Anh Duong; D. Haine; D. Garceau; J. Sampalis 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 274 KB

A multinational, randomised, 12-week stu

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

Open label, multicenter, 28-week extensi

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

✍ Brian R. Ott; Lesley M. Blake; Ethel Kagan; Malca Resnick; for the Memantine MEM 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 142 KB

Saffron in the treatment of patients wit

Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial

✍ S. Akhondzadeh; M. Shafiee Sabet; M. H. Harirchian; M. Togha; H. Cheraghmakani; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre